IP Library Patent Application 13389215
Patent Application
App. No. 13/389,215

PLASMA PROTEIN EFFECTIVE FOR SUPPRESSING COUGH

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
13/389,215
Abstract

The activated Factor XI is provided as an antitussive for cough caused by the stimulation at the tracheal bifurcation such as chronic cough. A pharmaceutical composition for prevention, treatment and/or symptom amelioration of cough, comprising a polypeptide chain as an active ingredient and a pharmaceutically acceptable carrier, wherein the polypeptide chain consists of a full length amino acid sequence constituting activated Factor XI (hereinafter also referred to as “FXIa”), the amino acid sequence with one or several amino acids therein being deleted, substituted or added, or a partial sequence of either of the above amino acid sequences, or an amino acid sequence comprising as a part any of the above amino acid sequences.

Claims (5)

1 . A pharmaceutical composition for prevention, treatment and/or symptom amelioration of cough, comprising a polypeptide chain as an active ingredient and a pharmaceutically acceptable carrier,

wherein the polypeptide chain consists of a full length amino acid sequence constituting activated Factor XI (hereinafter also referred to as “FXIa”), the amino acid sequence with one or several amino acids therein being deleted, substituted or added, or a partial sequence of either of the above amino acid sequences, or an amino acid sequence comprising as a part any of the above amino acid sequences.

2 . The pharmaceutical composition according to claim 1 , wherein the cough is caused by stimulation at the tracheal bifurcation.

3 . A method of prevention, treatment and/or symptom amelioration of cough in a mammal, comprising administering to the mammal an effective amount of a full length amino acid sequence constituting activated Factor XI (hereinafter also referred to as “FXIa”), the amino acid sequence with one or several amino acids therein being deleted, substituted or added, or a partial sequence of either of the above amino acid sequences, or an amino acid sequence comprising as a part any of the above amino acid sequences.

4 . The method according to claim 3 , wherein the cough is caused by stimulation at the tracheal bifurcation.

Assignments (2)
CORPORATE ADDRESS CHANGE Recorded Jan 16, 2013
From: THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE
To: THE CHEMO-SERO THERAPEUTIC RESEARCH INSTITUTE
Reel/Frame 029637/0102 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 17, 2012
From: KAMEI, SHINTARO; SHINDOME, ASAMI; HAMAMOTO, TAKAYOSHI; MAEDA, HIROAKI; HIRASHIMA, MASAKI; OKUDA, SACHIO; UMEHASHI, MISAKO; OGAWA, SACHIE; IMUTA, MEGUMI; AKAIKE, NORIO; TAKAHAMA, KAZUO; WADA, RYOKO
To: THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE; GINKYO ACADEMY KUMAMOTO HEALTH SCIENCE UNIVERSITY; NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY
Reel/Frame 028228/0217 →